Cosmetic neuropeptide
Syn-Ake
Syn-Ake after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- Syn-Ake
- Symbol
- SYA
- Family
- Cosmetic and copper peptides
- Parts
- 12
- References
- 8
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Syn-Ake is the trade name of a cosmetic ingredient whose INCI name is dipeptide diaminobutyroyl benzylamide diacetate.1,3 The manufacturer's brochure describes it as a "Synthetic tripeptide with mol weight below 500 Da", while the INCI name says dipeptide.1 The manufacturer sells it as a "Preservative-free, glycerine-based aqueous solution" that "mimics the essential amino acid sequence of the Waglerin-1 functionality".3 Waglerin-1 is a peptide from the venom of the temple viper, Tropidolaemus wagleri.1 The app lists it as a cosmetic neuropeptide applied to the skin, and its notes say no actual venom is used.3 The app grades the evidence as limited. The authors of the one peer-reviewed human study identified write that "there is limited published research" on its anti-wrinkle effects.2
How it works
The manufacturer's product page says that in vitro the ingredient "is considered as an antagonist at the muscular nicotinic acetylcholine receptor (mnAChR)".3 It states that the receptors are "reversibly blocked", the ion channel stays closed and facial muscles are relaxed.3 The brochure reports a cell test of the tripeptide at 0.5 mM, in which the frequency of contraction of innervated muscle cells was measured over time after treatment, and labels the result "Reduces muscle cell contraction" and "Fully reversible".1 The brochure gives no sample size, statistical method or peer-reviewed publication for this cell test.1 The authors of the serum study say the ingredient "also works similarly to BoNT by blocking signal transduction and relaxing the muscles in the treated area", where BoNT is botulinum toxin.2 No head-to-head comparison with botulinum toxin was identified in PubMed or ClinicalTrials.gov.
Where waglerin-1 comes from
Debono and colleagues, Journal of Molecular Evolution, 2017, describe waglerin peptides as having an "industrial application in skin cream products to paralyse facial muscles and thus reduce the incidence of wrinkles".4 They report that the peptides "are the result of de novo evolution within the prepro region of the C-type natriuretic peptide gene in Tropidolaemus venoms".4 Their record lists two authors at Alphabiotoxine Laboratory, a company; the letter is a sequence-evolution analysis and not a study of the cosmetic ingredient.4
Animal and tissue studies of waglerin-1, the toxin that is mimicked
These studies concern the natural 22-residue toxin given by injection or applied to nerve-muscle preparations, not the topical cosmetic peptide. McArdle and colleagues, Journal of Pharmacology and Experimental Therapeutics, 1999, concluded that "Waglerin-1 selectively blocks the mouse muscle nicotinic acetylcholine receptor containing the epsilon-subunit".5 In that work adult mice lacking the epsilon-subunit gene resisted the lethal effect, and neonatal mice also resisted it.5 Waglerin-1 reduced the end-plate response of adult wild-type mice to applied acetylcholine with an IC50 of 50 nM, and the work was supported by US National Institute of Neurological Disorders and Stroke grants.5 Tsai and colleagues, Toxicon, 1995, found that the toxin reversibly inhibited indirectly elicited twitch tension in mouse diaphragm while "the directly elicited twitch tension was not affected".6 They concluded that it "acts on both presynaptic and postsynaptic sites of the mouse motor endplate", with the presynaptic effect apparently more potent.6 Lin and colleagues, Toxicon, 1995, reported that in anesthetized mice "i.v. administration of waglerin-I at 0.5 microgram/g produced respiratory failure within 5 min".7 They concluded that neuromuscular block was the primary cause of death in mice, and that rats were resistant, with only transient hypotension at up to 10 micrograms/g intravenously.7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 1–4%
- Route
- Topical
- Time to peak
- ~0.5 h
Sources in this part
The second column of the table holds the app's own figures; the third holds what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~4 h | No half-life is reported in the sources retrieved |
| Bioavailability | 95% | No bioavailability figure is reported in the sources retrieved |
| Time to peak | ~0.5 h | No time to peak is reported in the sources retrieved |
| Systemic exposure | Notes say negligible systemic absorption | The sources retrieved report no blood or tissue measurement of the peptide2,1 |
| Duration of effect | Duration of 12 h in the app | The brochure's cell test in cultured innervated muscle cells is labelled "Fully reversible"; it gives no duration in people1 |
The app's own notes state that systemic pharmacokinetic tracking is not applicable to a topical ingredient and that the modelled curve does not really reflect how it works. The app's figures of 4 hours and 95% therefore have no figure from a source beside them, and none of the sources retrieved supports or contradicts them.
Human studies
The sources describe four tests in people, two clinical studies of a five-active serum in one paper and two manufacturer placebo-comparison cream tests; none of the four tests the peptide on its own against a vehicle in a report the sources show as peer-reviewed, and zhu2026 cites a further placebo-comparison trial of a 4% formulation that was not retrieved.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Zhu and colleagues, Study 1, Int J Cosmet Sci 20262 | Prospective single-arm, single-centre, no control group; L'Oréal-funded2 | 50 Chinese female participants analysed, all completed2 | Five-active serum twice daily on the whole face, 12 weeks; Syn-Ake at 2%2 | Dermatologist wrinkle scores improved 35% to 69% by week 12 across nine sites; no adverse events reported2 |
| Zhu and colleagues, Study 2, Int J Cosmet Sci 20262 | Prospective single-arm, single-centre, no control group; dynamic wrinkles under smile2 | 49 enrolled, 7 lost to follow-up, 42 completed2 | Same five-active serum twice daily, 8 weeks2 | Smile-expression wrinkle scores fell 10% (under-eye), 13% (nasolabial folds) and 11% (crow's feet); no adverse events reported2 |
| Manufacturer test of a 4% cream, DSM brochure 20201 | Placebo-comparison; brochure gives no peer-reviewed report, funder statement or blinding detail1 | 15 volunteers per group, aged 40 to 601 | Cream with Syn-Ake 4% or placebo, twice daily, 28 days1 | "Up to 52% wrinkle reduction after 28 days"; the brochure's chart for the same test carries labels of –21%, –20% and –15%; measurable wrinkle reduction in 73% and smoothing in 80% of volunteers1 |
| Manufacturer "Mothers & Daughters" test, dsm-firmenich product page3 | Placebo-comparison; the page text gives no peer-reviewed report or funder statement3 | 100 volunteers, 25 per group3 | Cream with Syn-Ake 4%, twice daily, 4 weeks3 | The page text retrieved gives no numeric result3 |
Sources in this part
Deeper analysis: Zhu and colleagues, serum with two peptides, Int J Cosmet Sci 2026
Zhu and colleagues at L'Oréal Research and Innovation centres in Shanghai, Clark (New Jersey) and Kawasaki reported one ex vivo test and two clinical studies of a serum with five actives: acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract.2 The record lists "L'Oreal Research & Innovation" as the grant, every listed author has an L'Oréal affiliation, and the conflict statement reads "The authors declare no conflicts of interest".2 The authors note that "their combined impact has not been previously studied", and no arm of either clinical study received the dipeptide alone.2 Any result below therefore belongs to the whole serum and cannot be assigned to Syn-Ake.2
In the ex vivo test, skin explants were exposed to UV radiation and treated, with three skin samples in each group.2 Against the negative control, Formula 1 was associated with a 53% reduction in MMP-1 and with increases in collagen fibres (86%) and collagen type I (289%), type III (71%), type IV (109%) and type XVII (37%).2 The authors write that "the positive control and Formula 2 yielded more favourable outcomes in the ex vivo model relative to Formula 1", attributing this to preservatives in the finished serum.2 In the explants, the five-active combination without vehicle raised collagen type I by 167% against 85% for a two-peptide combination, and collagen type IV by 229% against 162%.2
In the two clinical studies, participants applied the serum twice a day to the entire face, including the eye area.2 The authors describe "two prospective, single-arm, single-centre trials involving Chinese female participants", assessed by a dermatologist on a modified Griffith 10-point scale.2 Study 1 enrolled 50 participants for clinical evaluation, all of whom completed it; a further 24 were included in the questionnaire surveys only, one of whom withdrew, giving 73 who completed the survey.2 At 12 weeks, mean dermatologist scores had improved by 58% for forehead wrinkles, 69% for fine lines on the forehead, 47% for glabellar wrinkles and 35% for inter-ocular wrinkles, with 39% for crow's feet, 55% for under-eye wrinkles, 55% for cheek folds, 44% for nasolabial folds and 44% for wrinkles at the corner of the lips.2 Instrument measures were smaller than the clinical scores: forehead wrinkle count fell 29%, their length 9% and their area 11%.2 Epidermal thickness fell by 57% while dermal thickness rose by 12%, and "there were no significant differences in the combined thickness of both layers compared with the baseline".2 Study 2 enrolled 49 participants and 7 were lost to follow-up, leaving 42.2 Under a smile, scores fell 10% for under-eye wrinkles, 13% for nasolabial folds and 11% for crow's feet, a smaller change than for static wrinkles.2 The authors report that "No adverse events were reported in any of the clinical studies".2 They name two limitations: "The absence of a control group may have influenced the interpretation of the results", and a population "limited to Chinese patients, which may restrict the generalizability of the findings to other ethnic groups".2 The authors cite an earlier trial of a formulation with 4% of the dipeptide that "reported a significant decrease in wrinkle area and length on the forehead compared with placebo after 4 weeks of use", and suggest "a possible synergistic interaction among the five active ingredients" in their own serum.2
Deeper analysis: the manufacturer's 4% cream tests
The DSM brochure states that Syn-Ake at 4% "was compared to a placebo" in a cream applied to the forehead twice daily for 28 days, with 15 volunteers per group aged 40 to 60.1 Its results panel states "Up to 52% wrinkle reduction after 28 days", with measurable wrinkle reduction in 73% and a measurable smoothing effect in 80% of volunteers.1 The brochure says the forehead was treated yet reports measurements "on the crow’s feet", and gives no randomisation, blinding, funder statement or author list.1 This is the maker's own marketing document, written for business customers, and its disclaimer states that its information "does not constitute or provide scientific or medical advice".1 The product page describes a second test of the 4% cream against placebo, twice daily for 4 weeks, in 100 volunteers with 25 per group, and the page text retrieved gives no numeric result.3
Doses reported in studies and on labels
The app's typical range is 1 to 4%, which matches the concentration range the manufacturer suggests for formulators.1
| Source | Context | Concentration | Application and length | Note |
|---|---|---|---|---|
| DSM brochure, 20201 | Manufacturer's suggested concentration in cosmetic products | 1-4% | Not stated | Marketing document, not a label or regulator document |
| DSM brochure, 20201 | 15 per group, placebo comparison | 4% | Twice daily, 28 days | Forehead application stated; crow's feet measured |
| dsm-firmenich page3 | 100 volunteers, 25 per group, placebo comparison | 4% | Twice daily, 4 weeks | No numeric result in the page text |
| Zhu and colleagues, 20262 | Single-arm serum study, 50 and 42 participants | 2% in a five-active serum | Twice daily, 12 weeks (Study 1) and 8 weeks (Study 2) | Syn-Ake not tested alone |
| Earlier trial cited by Zhu and colleagues2 | Placebo comparison, forehead wrinkles | 4% | 4 weeks | Described secondhand; not retrieved |
Sources in this part
Side effects reported
Zhu and colleagues report "No adverse events were reported in any of the clinical studies" for the five-active serum, in studies of 50 and 42 participants without a control group.2 The manufacturer lists "Safe for topical applications" as a product feature, without a safety dataset in the documents retrieved.1 The toxin that the peptide mimics produced respiratory failure within 5 min in anesthetized mice given it intravenously, which is a finding about waglerin-1 and not about the topical ingredient.7 Lin and colleagues found rats resistant, and McArdle and colleagues found that adult mice lacking the epsilon-subunit gene and neonatal mice resisted the lethal effect of waglerin-1.7,5
Regulatory and anti-doping status
Sources in this part
The manufacturer's product page points to a "Regulatory Status China Statement" and its brochure carries a "CHINA LISTED" mark; neither document retrieved gives a regulator's assessment.3,1 No European, US or other regulator document on the ingredient was retrieved. The 2026 WADA Prohibited List text retrieved does not name Syn-Ake, dipeptide diaminobutyroyl benzylamide diacetate or waglerin.8 Its S0 class prohibits "any pharmacological substance" not addressed elsewhere and "with no current approval by any governmental regulatory health authority for human therapeutic use", and the list does not say whether a cosmetic ingredient falls within it.8
What is not known
Sources in this part
No pharmacokinetic study of Syn-Ake, in skin, blood or any tissue, was identified in PubMed. The app's half-life of 4 hours, bioavailability of 95% and time to peak of 0.5 hours have no figure from a source in the documents retrieved. No trial isolating Syn-Ake from other ingredients, no independent replication and no trial longer than 12 weeks were identified. Whether the peptide reaches muscle receptors after topical application, and at what concentration, is not shown in the sources retrieved; the receptor action is described from in vitro work.3 The manufacturer's two documents call the ingredient a tripeptide and name it a dipeptide, and none of the sources retrieved resolves the difference.1
Frequently asked questions
What is Syn-Ake?
What is the half-life of Syn-Ake?
The app lists a half-life of about 4 hours, and none of the sources retrieved reports a half-life for Syn-Ake. The app's notes add that systemic pharmacokinetic tracking is not applicable to this topical ingredient.
Is Syn-Ake made from snake venom?
The manufacturer describes it as a "Synthetic tripeptide" that mimics a peptide found in temple viper venom.1 The app's notes likewise say no actual venom is used.
How does Syn-Ake work?
Has Syn-Ake been tested in people?
A 2026 study of a five-active serum with 2% Syn-Ake, funded by a L'Oréal grant and written by authors all affiliated with L'Oréal, in 50 and 42 Chinese female participants without a control group, reported improved wrinkle scores and no adverse events.2 The manufacturer reports separate 4% cream tests against placebo, but they are not peer-reviewed reports in the sources retrieved.1
Is Syn-Ake the same as botulinum toxin?
The serum study's authors say it "works similarly to BoNT", meaning botulinum toxin, but no comparison between the two was identified.2
What side effects has Syn-Ake been reported to cause?
The one peer-reviewed human study reported no adverse events, in a serum with five actives and without a control group.2
Guides, tools and comparisons
References
- DSM Nutritional Products. SYN-Peptides: SYN-AKE. Product brochure, 2020. DSM brochure
- Zhu M, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. Int J Cosmet Sci 2026;48(5):913-925. PMID 41668671
- dsm-firmenich. SYN-AKE. Digital product catalogue entry. dsm-firmenich product page
- Debono J, et al. Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream. J Mol Evol 2017;84(1):8-11. PMID 27864608
- McArdle JJ, et al. Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor. J Pharmacol Exp Ther 1999;289(1):543-550. PMID 10087048
- Tsai MC, et al. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon 1995;33(3):363-371. PMID 7638875
- Lin WW, et al. A study on the cause of death due to waglerin-I, a toxin from Trimeresurus wagleri. Toxicon 1995;33(1):111-114. PMID 7778124
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list